Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + capecitabine
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Gemcitabine + capecitabine is a combination chemotherapy regimen primarily used in the treatment of pancreatic cancer, often referred to as "GemCap" or "CapGem". Gemcitabine is administered intravenously and acts as a nucleoside analog, interfering with DNA synthesis by being incorporated into DNA and inhibiting DNA polymerase activity. Capecitabine is an oral prodrug that is converted in vivo to 5-fluorouracil (5-FU), which inhibits thymidylate synthase and disrupts both DNA and RNA synthesis. The combination works synergistically to prevent cancer cell division and proliferation. This regimen may be used as adjuvant therapy following surgery or for advanced disease[1][2][3][4][5][8].
- Brand names
- XelodaGemzar
- Other names
- GemCapCapGemCG
02
Targets
DNA polymerase familyRNR (Ribonucleotide reductase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on gemcitabine + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + capecitabine.